Paromomycin
Treatment for Visceral Leishmaniasis
Typical Dosage: 15 mg/kg/day intramuscularly for 21 days
Effectiveness
85%
Safety Score
65%
Clinical Trials
11
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
15 mg/kg/day intramuscularly for 21 days
Time to Effect
2-3 weeks
Treatment Duration
21 days
Evidence Quality
MODERATENumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$4,000
Side Effect Mgmt:$1,000
Total Annual:$5,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$6,824
Cost per Remission
$7,250
Comparison vs Sodium Stibogluconate
Cost Difference
$-3,200/year
Less expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Paromomycin Outcomes
for Visceral Leishmaniasis
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+80%
Common Side Effects
Injection site pain
+30%
Nephrotoxicity (creatinine elevation)
+10%
Ototoxicity (hearing loss, tinnitus)
+3%
Active Clinical Trials
1 active trial recruiting for Paromomycin in Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
NCT04342715ACTIVE NOT RECRUITING
216 participants
OBSERVATIONAL
Nairobi, Kenya
Started: May 22, 2022
Completed Clinical Trials
10 completed trials for Paromomycin in Visceral Leishmaniasis
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
NCT00629031COMPLETEDPHASE3
329 participants
INTERVENTIONAL
Varanasi, India
Started: Feb 1, 2008
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
NCT01328457COMPLETEDNA
120 participants
INTERVENTIONAL
Bhaluka, Bangladesh +2 more
Started: Jan 1, 2011
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
NCT00604955COMPLETEDPHASE4
2K participants
INTERVENTIONAL
Agam Kuan, Patna, India +6 more
Started: Oct 1, 2007
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
NCT00255567COMPLETEDPHASE3
1.14K participants
INTERVENTIONAL
Arba Minch, Ethiopia +4 more
Started: Nov 1, 2004
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
NCT03129646COMPLETEDPHASE3
439 participants
INTERVENTIONAL
Ābderafī, Ethiopia +6 more
Started: Jan 24, 2018
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
NCT00216346COMPLETEDPHASE3
667 participants
INTERVENTIONAL
Agam Kuan, Patna, India +3 more
Started: Jun 1, 2003
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
NCT00696969COMPLETEDPHASE3
634 participants
INTERVENTIONAL
Muzaffarpur, India +1 more
Started: Jun 1, 2008
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
NCT01122771COMPLETEDPHASE3
602 participants
INTERVENTIONAL
Bhaluka, Bangladesh +3 more
Started: May 1, 2010
Combination Therapy in Indian Visceral Leishmaniasis
NCT00523965COMPLETEDPHASE3
624 participants
INTERVENTIONAL
Muzaffarpur, India
Started: Sep 1, 2007
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
NCT05957978COMPLETEDPHASE2
52 participants
INTERVENTIONAL
Gonder, Ethiopia
Started: Mar 29, 2024